C12N 2830/85
Mammalian
Official title: mammalian
C12N2830/85 (Mammalian) appears on 692 US grants and 728 published applications in this corpus.
Search patents in C12N- Granted patents
- 692
- Published applications
- 728
- Assignees
- 429
- Inventors
- 1,420
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 4 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 9 | 0 |
| 1996 | 20 | 0 |
| 1997 | 39 | 0 |
| 1998 | 52 | 0 |
| 1999 | 48 | 0 |
| 2000 | 39 | 0 |
| 2001 | 32 | 11 |
| 2002 | 30 | 69 |
| 2003 | 35 | 88 |
| 2004 | 17 | 69 |
| 2005 | 32 | 66 |
| 2006 | 24 | 53 |
| 2007 | 36 | 42 |
| 2008 | 20 | 40 |
| 2009 | 18 | 23 |
| 2010 | 22 | 29 |
| 2011 | 21 | 26 |
| 2012 | 17 | 22 |
| 2013 | 16 | 20 |
| 2014 | 20 | 24 |
| 2015 | 16 | 15 |
| 2016 | 18 | 15 |
| 2017 | 18 | 27 |
| 2018 | 10 | 15 |
| 2019 | 10 | 15 |
| 2020 | 16 | 19 |
| 2021 | 11 | 10 |
| 2022 | 10 | 16 |
| 2023 | 5 | 3 |
| 2024 | 2 | 4 |
| 2025 | 4 | 4 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Regulatable adeno-associated virus (AAV) vector2 Jun 2026US 12,642,869 B2Georg-August-UniversitäT GöTtingen Stiftung öFfentlichen Rechts, UniversitäTsmedizin
- Methods and compositions for reducing the immunogenicity of chimeric notch receptors5 May 2026US 12,617,825 B2Cell Design Labs, Inc.
- Compositions and methods for anti-TnMUC1 gold CAR t-cells17 Mar 2026US 12,576,135 B2Chimera Bioengineering, Inc.
- Muscle-specific nucleic acid regulatory elements and methods and use thereof23 Sep 2025US 12,419,972 B2Universiteit Gent
- Liver-specific nucleic acid regulatory elements and methods and use thereof9 Sep 2025US 12,409,236 B2Life Sciences Research Partners VZW
- Utr for improving translation efficiency and/or stability of rna molecule and use thereof23 Jul 2026US 2026/0209719 A1Shenzhen Shenxin Biotechnology Co., Ltd.
- Recombinant promoter system specifically inducing high level of gene expression after t cell activation9 Jul 2026US 2026/0191906 A1Xuzhou Medical University
- Human and murine oprm1 promoters and uses thereof25 Jun 2026US 2026/0174790 A1The Board of Trustees of the Leland Stanford Junior University
- Expression and secretion system30 Oct 2025US 2025/0333723 A1Genentech, Inc.
- Bidirectional chef1 vectors9 Oct 2025US 2025/0313852 A1AGC Biologics S.p.A.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Transgenic non-human animals for producing heterologous antibodies679US 5,814,318 AGenPharm International, Inc. · 1998